ALFA Filings
Every announcement, straight from the exchange
Every Jenburkt Pharmaceuticals other announcement announcement on NSE and BSE, newest first, each with its own page.
Time
5 announcements with these filters
Jenburkt Pharmaceuticals submitted a certificate under SEBI Regulation 74(5) regarding share dematerialization for the quarter ended September 30, 2026.
Jenburkt Pharmaceuticals clarified its shares are permitted to trade on NSE without a listing application. The shares remain listed on BSE under the Permitted to Trade category.
Jenburkt Pharmaceuticals approved shifting its registered office within Mumbai effective July 21, 2026. Contact details and ROC jurisdiction remain unchanged.
Jenburkt Pharmaceuticals Limited has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. Issued by Nilesh Shah & Associates, the report confirms general compliance with SEBI regulations, though it notes minor clarifications were previously required by the BSE regarding financial result filings.
Jenburkt Pharmaceuticals submitted a compliance certificate for the quarter ended March 31, 2026, confirming that securities received for dematerialization were processed, mutilated, and cancelled by its Registrar and Transfer Agent, Bigshare Services Pvt. Ltd. This is a routine regulatory disclosure with no material financial impact.